Search Results 1491-1500 of 121950 for Cycle

  1. Olaparib and Atezolizumab Either Alone or in Combination in Treating Patients With Stage III-IV Triple Negative Breast Cancer - Mayo Clinic

    ... Cycle 1, Day 1. Patients who have received acute, low dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea) may ...

  2. Aortic dissection - Doctors and departments - Mayo Clinic

    So in many ways, it's a cycle. It can start with as simple as an idea worked on in a laboratory, brought to the patient bedside, and if everything goes ...

  3. Delayed sleep phase - Doctors and departments - Mayo Clinic

    So in many ways, it's a cycle. It can start with as simple as an idea worked on in a laboratory, brought to the patient bedside, and if everything goes ...

  4. TUESDAY Q & A: Rest is important after a concussion

    Common concussion symptoms include headache, confusion, difficulty with memory and concentration, changes in sleep-wake cycles, mood changes, dizziness ...

  5. Epoetin alfa (injection route) - Side effects & dosage - Mayo Clinic

    Epoetin injection is used to treat anemia in patients with chronic kidney disease (CKD) who may or may not be on dialysis. This medicine may also be used to ...

  6. A Study To Compare Standard Therapy To Treat Hodgkin Lymphoma To The Use Of Two Drugs, Brentuximab Vedotin And Nivolumab - Mayo Clinic

    ... cycles of doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD) chemotherapy. ... cycle 1, day 1. Patients with peripheral neuropathy > grade 1 at the time of ...

  7. Gastrointestinal Stromal Tumor (GIST) Clinical Trials - Mayo Clinic Research

    Approximately 358 patients will be randomized in a 1:1 ratio to DCC-2618 150 mg once daily (QD) (continuous dosing for 6 week cycles) ... cycle in subjects with ...

  8. Minority-inclusive Imaging Biomarker-based End of Therapy Trial for 177Lu-PSMA-617 - Mayo Clinic

    ... cycle of 177Lu PSMA-617 per prescribing information * Hemoglobin (Hgb) ≥ 8 g/dL * Platelets ≥ 75,000/mm\^3 * Neutrophils ≥ 100/mm\^3 * Estimated ...

  9. Safety/Efficacy of MEDI-551 in Combination With Immunomodulating Therapies in Subjects With Aggressive B-cell Lymphomas - Mayo Clinic

    Receipt of any experimental therapy, mAb, cancer vaccine, chemotherapy or small molecule within 28 days prior to Cycle 1 Day 1 or 5 half-lives of that ...

  10. Ibrutinib in Treating Minimal Residual Disease in Patients With Chronic Lymphocytic Leukemia After Front-Line Therapy - Mayo Clinic

    Patient must have completed a frontline induction therapy (minimum of 2 treatment cycles). ... cycle (due to toxicity or any other reason) will not be considered ...